MediCor Closes $50 Million Senior Secured Convertible Debt Financing and Debt Restructuring

[Guest guest]

http://biz./prnews/060427/lath059.html?.v=52

MediCor Closes $50 Million Senior Secured Convertible

Debt Financing and Debt Restructuring

Thursday April 27, 9:00 am ET

LAS VEGAS, April 27 /PRNewswire-FirstCall/ -- MediCor

Ltd. (OTC Bulletin Board: MDCR - News), the world's

third largest manufacturer and distributor of breast

implants, today announced it has raised $50 million in

a private placement. The financing involved the sale

of senior secured convertible notes and warrants to

purchase common stock. Concurrently, Sirius Capital

LLC, a private equity investment fund affiliated with

the Company's Chairman and founder, K. McGhan,

converted $37.5 million of outstanding loans to the

Company into a subordinated convertible note, with

similar terms as the senior secured convertible notes,

and a warrant to purchase common stock. Certain of the

Company's remaining debt was subordinated to the new

senior notes. UBS Investment Bank advised the Company

and provided private placement services in connection

with the transaction.

ADVERTISEMENT

About MediCor Ltd.

MediCor was founded by K. McGhan, Chairman of

the Board, and a pioneer of the modern day breast

implant industry. The Company acquires, develops,

manufactures and markets products for medical

specialties in the aesthetic, plastic and

reconstructive surgery and dermatology markets.

Products include surgically implantable prostheses for

aesthetic, plastic and reconstructive surgery and scar

management products, all of which are sold worldwide

to hospitals, surgery centers and physicians through a

combination of distributors and direct sales

personnel. MediCor's strategy is to be the leading

integrator of selected international medical device

technologies and corporations. The Company intends to

achieve that goal through the expansion of its

existing product lines and offerings and through the

acquisition of companies and other assets, including

intellectual property rights or distribution rights.

Forward-Looking Statements

This release may contain forward-looking statements

within the meaning of the Private Securities

Litigation Reform Act of 1995. Such statements are

based upon the current beliefs and expectations of

MediCor's management and are subject to significant

risks and uncertainties. Actual results may differ

from those set forth in the forward-looking

statements.

There are a number of factors that could cause actual

results or events to differ from those set forth in

the forward-looking statements, including: risks that

the Company will not be able to obtain additional

financing to fund its growth in accordance with its

strategy; the risk of failure to or delay in obtaining

regulatory approval to market the Company's products;

risks that competitors will obtain regulatory approval

to market their products before the Company obtains

similar approval; risks related to integration of

acquired businesses; the risk of instability in the

U.S. or international capital markets; disruption from

transactions disrupting normal business operations;

the outcome of legal proceedings; and the risk of new

and changing regulations in the U.S. and

internationally. Additional factors that could cause

MediCor's results to differ materially from those

described in the forward-looking statements can be

found in MediCor's Annual Report on Form 10-KSB for

the year ended June 30, 2005, and in subsequent

reports filed quarterly on Form 10-Q, all of which

have been filed with the Securities and Exchange

Commission and is available at the Securities and

Exchange Commission's Internet site

(http://www.sec.gov).